EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Guide to the FDA’s Expedited Drug Programs

Alexandra Fillion

Science and Technology Law Review · 31.10.2026

DOI: 10.52214/xvzx2z66 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science and Technology Law Review, online erschienen am 31.10.2026. Verfasst von Alexandra Fillion. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Author: Alexandra Fillion '28 | Editor: Samantha Wachs The Ordinary Drug Review Process The Food and Drug Administration (FDA) oversees the development and marketing of drugs in the United States, aiming to ensure that treatments are safe and effective for patients. To fulfill this ambition, the FDA subjects every new drug application to a thorough approval process. [1]. Before a clinical trial can begin, a drug sponsor—an individual or organization intending to conduct a clinical trial—must prepare an investigational new drug (IND) application for submission to the FDA. [2], [3]. If approved, the IND functions as a permit for the drug sponsor to begin the clinical trial. [3]. Once clinical trial evidence is gathered, it is compiled into a second application called a New Drug Application (NDA) which, if approved, permits the drug sponsor to market the drug for its intended use. [4]. Conducting clinical trials, and obtaining FDA approval can take several years. To help new drugs reach patients sooner, the FDA established four programs to expedite drug development and review: Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval. [5]. The Commissioner’s National Priority Voucher (CNPV) pilot program adds a fifth option. [6]. Fast Track The Fast Track designation is for a drug that is intended to treat a serious condition. The drug’s pre-clinical (pre-IND), or clinical trial data must show the potential to address an unmet medical need. The drug should provide a new or superior therapy for patients compared to existing drugs. Because sponsors may request Fast Track designation with or after the submission of the IND application, the evidence required to qualify for Fast Track varies depending on the stage at which the designation request is made. Benefits of Fast Track designation include closer guidance from the FDA regarding effective clinical trial design and evidence collection, and a rolling review process of NDA materials as they are submitted by the drug sponsor. [7]. Breakthrough Therapy Like Fast Track designation, Breakthrough Therapy designation is for a drug that is intended to treat a serious condition. However, Breakthrough Therapy designation requires preliminary clinical evidence that a drug may offer a substantial improvement over an existing drug on a clinically significant endpoint. This means that a measured disease outcome related to morbidity or mortality, like a severe disease symptom, must be meaningfully improved by the drug. Breakthrough Therapy designation provides the same benefits as Fast Track designation (FDA guidance and rolling review) but with more intensive guidance from the FDA on efficient drug development. Additionally, a drug with Breakthrough Therapy designation could also be eligible for Priority Review. [7]. Priority Review Like the two preceding designations, Priority Review designation applies to drugs intended to treat a serious condition. In addition, the drug must offer a significant improvement in treatment safety or effectiveness. This improvement can be shown in several ways including reducing a treatment-limiting adverse reaction, meaningfully improving patient compliance, treating a new subpopulation, or preventing a disease more effectively. The benefit of Priority Review designation is that the NDA can be reviewed in 6 months, as opposed to the standard 10-month review timeline. [7]. Accelerated Approval Some drug outcomes, like longer survival, require years to measure; other outcomes may involve infrequent events that require large studies to evaluate. Where a trial’s duration or size is a limiting factor, Accelerated Approval can provide earlier access to drugs that treat serious diseases. To justify Accelerated Approval, the drug must show an effect on a measurement—such as a laboratory measurement or tumor shrinkage—that is reasonably likely to predict the drug’s clinical benefit. Like the three preceding designations, the treatment must also offer a meaningful advantage over existing therapies. The distinguishing feature of this pathway is that approval is based on predictive evidence before the anticipated clinical benefit has been confirmed. [7]. Commissioner’s National Priority Voucher (CNPV) Introduced in June 2025, the CNPV pilot reduces drug review times to 1-2 months. The drugs selected for this pathway must align with a critical national health priority: (1) a public health crisis; (2) an innovative breakthrough therapy; (3) a substantial unmet medical need; (4) domestic manufacturing and supply chain resilience; or (5) improved access through affordability. In June 2026, the FDA hosted a public hearing to collect feedback from industry representatives, and clinicians on the new program. The attendees called for clearer eligibility criteria, and requested that the FDA explain how it applied and weighed the broad national priorities when selecting drugs for CNPV. Several participants requested public selection rationales and questioned how the pilot adds to the existing expedited review programs. A former FDA Acting Chief Counsel warned that some approvals could face legal challenges alleging that drug selections were awarded arbitrarily or based on considerations outside the FDA’s authority. A former FDA associate commissioner cautioned that including drug pricing and domestic manufacturing as national priorities could introduce political preferences into the selection process. [8]. The FDA has committed to considering the feedback and has stated that it intends to publish additional guidance for drug sponsors as the program develops. [8], [9]. Whether those materials will clarify eligibility criteria and explain how voucher recipients are selected remains an open question. Confidence in the program depends on a transparent and predictable selection process that advances the FDA’s goal of bringing safe and effective drugs to patients. Citations [1] Development & Approval Process | Drugs, U.S. Food & Drug Admin. (Oct. 11, 2026, 9:00 AM), https://www.fda.gov/drugs/development-approval-process-drugs [2] 21 C.F.R. § 312.3(b) (2025). [3] 21 C.F.R. § 312.23 (2025). [4] New Drug Application (NDA), U.S. Food & Drug Admin. (Oct. 11, 2026, 9:00 AM), https://www.fda.gov/drugs/types-applications/new-drug-application-nda [5] Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, U.S. Food & Drug Admin. (Oct. 11, 2026, 9:00 AM), https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review [6] Commissioner's National Priority Voucher (CNPV) Pilot Program, U.S. Food & Drug Admin. (Oct. 11, 2026, 9:00 AM), https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program [7] U.S. Food & Drug Admin., Guidance for Industry: Expedited Programs for Serious Conditions–Drugs and Biologics (2014). [8] Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing, U.S. Food & Drug Admin. (Oct. 11, 2026, 9:00 AM), https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/commissioners-national-priority-voucher-cnpv-pilot-program-public-hearing-06042026 [9] FAQs: Commissioner’s National Priority Voucher Pilot Program, U.S. Food & Drug Admin. (Oct. 11, 2026, 9:00 AM), https://www.fda.gov/news-events/press-announcements/faqs-commissioners-national-priority-voucher-pilot-program

Zitieren

APA

Fillion, A. (2026). A Guide to the FDA’s Expedited Drug Programs. Science and Technology Law Review. https://doi.org/10.52214/xvzx2z66

Vancouver

Fillion A. A Guide to the FDA’s Expedited Drug Programs. Science and Technology Law Review. 2026. doi:10.52214/xvzx2z66

BibTeX
@article{Fillion2026,
  author = {Fillion, Alexandra},
  title = {A Guide to the FDA’s Expedited Drug Programs},
  journal = {Science and Technology Law Review},
  year = {2026},
  doi = {10.52214/xvzx2z66}
}
Kostenlos starten →